{"commentary":{"count":13,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06580314\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06580314","nct_id":"NCT06580314","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06580314. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.","label":"Arm I (olaparib, bevacizumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.","label":"Arm II (olaparib, bevacizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-12-31","type":"ESTIMATED"},"conditions":["Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube High Grade Serous Adenocarcinoma","Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor","FIGO Stage III Ovarian Cancer 2014","FIGO Stage IV Ovarian Cancer 2014","Ovarian Carcinoma","Ovarian Carcinosarcoma","Ovarian High Grade Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Carcinosarcoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma"],"enrollment":{"count":880,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bevacizumab","type":"BIOLOGICAL"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Olaparib","type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"NRG Oncology","official_title":"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2034-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) at least 360 days after randomization (PFS360)","timeFrame":"From completing 360 days of maintenance therapy to disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) or death, whichever occurs first, assessed up to 5 years"}],"references":[],"start_date":{"date":"2025-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","url":"https://clinicaltrials.gov/study/NCT06580314"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06580314"}